Reports
Sale
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market: By Testing Type: Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Flexible Sigmoidoscopy, Others; By Imaging Type: Colonoscopy, Proctoscopy, CT Scan, Ultrasound, MRI, PET Scan; By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Outlook
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of colorectal cancer. It is expected to grow at a CAGR of 5.53% during the forecast period of 2024-2032, with the values likely to attain USD 1492.8 million by 2032.
Key Takeaways
- Recent studies suggest that Asia accounts for 49% of the total number of new cancer cases worldwide, with the incidence and mortality of colorectal cancer likely to reach 1,310,000 and 484,000, respectively, in China by 2044. This rising incidence fuels the demand for effective in-vitro screening tests.
- One of the major Asia Pacific in-vitro colorectal cancer screening tests market trends is the rising technological advancements in in-vitro diagnostic techniques that are leading to the development of minimally invasive screening methods. In February 2023, researchers from the University of Technology Sydney (UTS) developed an innovative static droplet microfluidic device that can detect cancer cells from blood samples.
- The rise in reimbursement policies ensures the accessibility and affordability of in-vitro screening methods, thereby boosting market size. In July 2023, the Guardant360® CDx liquid biopsy test developed by Guardant Health, Inc. received reimbursement approval in Japan for comprehensive genomic profiling (CGP) for advanced or metastatic solid tumor cancers.
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Analysis
In-vitro colorectal cancer (CRC) screening tests are diagnostic tests that are performed outside the body of the patient to detect markers or indications associated with colorectal cancer. These screening tests usually involve analyzing biological samples such as stool, blood, or tissue taken from the patient. The rising healthcare expenditure coupled with the heightened awareness regarding cancer screening and importance of early detection is contributing significantly to the Asia Pacific in-vitro colorectal cancer screening tests market growth.
The burden of cancer in Asia Pacific is witnessing a steady increase. Recent studies suggest that Asia accounts for 49% of the total number of new cancer cases worldwide, with half of them found in China. Further, it is estimated that the incidence and mortality of colorectal cancer are likely to reach 1,310,000 and 484,000, respectively, in China by 2044. The increased number of colorectal cancer cases can be attributed to the growing aging populations, sedentary lifestyles, and the prevalence of risk factors such as obesity and smoking. This rising incidence fuels the demand for effective diagnostic tests, which is expected to boost the Asia Pacific in-vitro colorectal cancer screening tests market share in the forecast period.
The continuous technological advancements in in-vitro diagnostic techniques are leading to the development of minimally invasive screening methods. In February 2023, researchers from the University of Technology Sydney (UTS) developed an innovative static droplet microfluidic device that can detect cancer cells from blood samples. This detection technology reduces the need for invasive biopsies for cancer screening by rapidly identifying tumor cells that enter the bloodstream after breaking away from the primary tumor. Such blood-based assays are gaining popularity due to their accuracy and ease of use and are likely to augment the Asia Pacific in-vitro colorectal cancer screening tests market demand.
The presence of a favorable regulatory environment and reimbursement policies in the region also shapes the market landscape. In July 2023, the Guardant360® CDx liquid biopsy test developed by Guardant Health, Inc. (a leading precision oncology company) received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for comprehensive genomic profiling (CGP) for advanced or metastatic solid tumor cancers including advanced colorectal cancer patients. The MHLW-approved test analyzes circulating tumor DNA (ctDNA) in a patient’s blood which can offer insights for therapy selection. The rise in reimbursement policies ensures the accessibility and affordability of in-vitro screening methods, thereby boosting the market size for approved diagnostic tests.
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Testing Type | Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Flexible Sigmoidoscopy, Others |
| Imaging Type | Colonoscopy, Proctoscopy, CT Scan, Ultrasound, MRI, PET Scan |
| End User | Hospitals, Clinics, Diagnostics Laboratories |
| Country | China, Japan, India, ASEAN, Australia, Others |
Asia Pacific In-vitro Colorectal Cancer Screening Tests Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche AG
- Abbott
- Siemens Healthineers AG
- Sysmex Corporation
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Myriad Genetics, Inc.
- Exact Sciences Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Testing Type |
|
| Breakup by Imaging Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Overview
3.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
3.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
4 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Landscape*
4.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests: Product Landscape
4.2.1 Analysis by Test Type
4.2.2 Analysis by Imaging Type
5 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
6.1 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
6.1.1 Market Overview
6.1.2 Fecal Occult Blood Tests
6.1.3 Biomarker Tests
6.1.4 CRC DNA Screening Tests
6.1.5 Flexible Sigmoidoscopy
6.1.6 Others
6.2 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
6.2.1 Market Overview
6.2.2 Colonoscopy
6.2.3 Proctoscopy
6.2.4 CT Scan
6.2.5 Ultrasound
6.2.6 MRI
6.2.7 PET Scan
6.3 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Clinics
6.3.4 Diagnostics Laboratories
6.4 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
6.4.1 Market Overview
6.4.2 China
6.4.3 Japan
6.4.4 India
6.4.5 ASEAN
6.4.6 Australia
6.4.7 Others
7 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
7.1 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
7.1.1 Market Overview
7.1.2 Fecal Occult Blood Tests
7.1.3 Biomarker Tests
7.1.4 CRC DNA Screening Tests
7.1.5 Flexible Sigmoidoscopy
7.1.6 Others
7.2 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
7.2.1 Market Overview
7.2.2 Colonoscopy
7.2.3 Proctoscopy
7.2.4 CT Scan
7.2.5 Ultrasound
7.2.6 MRI
7.2.7 PET Scan
7.3 China In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
7.3.1 Market Overview
7.3.2 Hospitals
7.3.3 Clinics
7.3.4 Diagnostics Laboratories
8 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
8.1 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
8.1.1 Market Overview
8.1.2 Fecal Occult Blood Tests
8.1.3 Biomarker Tests
8.1.4 CRC DNA Screening Tests
8.1.5 Flexible Sigmoidoscopy
8.1.6 Others
8.2 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
8.2.1 Market Overview
8.2.2 Colonoscopy
8.2.3 Proctoscopy
8.2.4 CT Scan
8.2.5 Ultrasound
8.2.6 MRI
8.2.7 PET Scan
8.3 Japan In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
8.3.1 Market Overview
8.3.2 Hospitals
8.3.3 Clinics
8.3.4 Diagnostics Laboratories
9 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
9.1 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
9.1.1 Market Overview
9.1.2 Fecal Occult Blood Tests
9.1.3 Biomarker Tests
9.1.4 CRC DNA Screening Tests
9.1.5 Flexible Sigmoidoscopy
9.1.6 Others
9.2 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
9.2.1 Market Overview
9.2.2 Colonoscopy
9.2.3 Proctoscopy
9.2.4 CT Scan
9.2.5 Ultrasound
9.2.6 MRI
9.2.7 PET Scan
9.3 India In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
9.3.1 Market Overview
9.3.2 Hospitals
9.3.3 Clinics
9.3.4 Diagnostics Laboratories
10 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
10.1 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
10.1.1 Market Overview
10.1.2 Fecal Occult Blood Tests
10.1.3 Biomarker Tests
10.1.4 CRC DNA Screening Tests
10.1.5 Flexible Sigmoidoscopy
10.1.6 Others
10.2 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
10.2.1 Market Overview
10.2.2 Colonoscopy
10.2.3 Proctoscopy
10.2.4 CT Scan
10.2.5 Ultrasound
10.2.6 MRI
10.2.7 PET Scan
10.3 ASEAN In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
10.3.1 Market Overview
10.3.2 Hospitals
10.3.3 Clinics
10.3.4 Diagnostics Laboratories
11 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
11.1 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
11.1.1 Market Overview
11.1.2 Fecal Occult Blood Tests
11.1.3 Biomarker Tests
11.1.4 CRC DNA Screening Tests
11.1.5 Flexible Sigmoidoscopy
11.1.6 Others
11.2 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
11.2.1 Market Overview
11.2.2 Colonoscopy
11.2.3 Proctoscopy
11.2.4 CT Scan
11.2.5 Ultrasound
11.2.6 MRI
11.2.7 PET Scan
11.3 Australia In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Diagnostics Laboratories
12 Regulatory Framework
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 F. Hoffmann-La Roche AG
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Abbott
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Siemens Healthineers AG
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Sysmex Corporation
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Beckman Coulter, Inc.
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Bio-Rad Laboratories, Inc
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Qiagen NV
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Thermo Fisher Scientific Inc.
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Myriad Genetics, Inc.
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Exact Sciences Corporation
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Asia Pacific In-vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific in-vitro colorectal cancer screening tests market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 5.53% during the forecast period of 2024-2032 and is likely to reach a market value of USD 1492.8 million by 2032.
The rising incidence rates of colorectal cancer and a growing preference for non-invasive screening methods are fuelling the demand for the market.
One of the significant trends in the market is the rising technological advancements in in-vitro diagnostic techniques. In February 2023, researchers from the University of Technology Sydney (UTS) developed an innovative static droplet microfluidic device that can detect cancer cells from blood samples.
Based on the testing type, the market is segmented into fecal occult blood tests, biomarker tests, CRC DNA screening tests, and flexible sigmoidoscopy, among others.
By imaging type, the market is divided into colonoscopy, proctoscopy, CT scan, ultrasound, MRI, and PET scan.
End users of the market are hospitals, clinics, and diagnostics laboratories.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are F. Hoffmann-La Roche AG, Abbott, Siemens Healthineers AG, Sysmex Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Qiagen NV, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., and Exact Sciences Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER